Filing Details

Accession Number:
0001127602-15-021101
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-06-22 06:47:02
Reporting Period:
2015-06-18
Filing Date:
2015-06-22
Accepted Time:
2015-06-22 06:47:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1082554 United Therapeutics Corp UTHR Pharmaceutical Preparations (2834) 521984749
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1193522 W Louis Sullivan C/O United Therapeutics Corporation
1040 Spring Street
Silver Spring MD 20910
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-06-18 30,000 $41.14 30,000 No 4 M Direct
Common Stock Disposition 2015-06-18 30,000 $185.78 0 No 4 D Direct
Common Stock Acquisiton 2015-06-18 15,000 $30.75 15,000 No 4 M Direct
Common Stock Disposition 2015-06-18 15,000 $185.60 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 D Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Share Tracking Award Disposition 2015-06-18 30,000 $0.00 30,000 $41.14
Common Stock Stock Options Disposition 2015-06-18 15,000 $0.00 15,000 $30.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2010-06-26 2019-06-26 No 4 M Direct
15,000 2009-04-29 2018-04-29 No 4 M Direct
Footnotes
  1. Exercise of a cash-settled share tracking award.
  2. Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
  3. This transaction was executed in multiple trades at prices ranging from $185.25 to $186.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.